\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[greek,ngerman,english]{babel}



\usepackage{float}








\begin{document}

\title{Protective Role of the Biofield Energy Treated Test Formulation on
Vital~ Organs Function using Cell-Based Assays}



\author[1]{Thomas Charles Slade}%
\author[1]{Mahendra Kumar Trivedi}%
\author[1]{Alice Branton}%
\author[1]{Dahryn Trivedi}%
\author[1]{Gopal Nayak}%
\author[1]{Sambhu Charan Mondal}%
\author[1]{Snehasis Jana}%
\affil[1]{Affiliation not available}%


\vspace{-1em}



  
  \date{May 18, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
Dysfunction of vital organs is the main concern for human health.
Therefore, it is necessary to homeostat the normal function of vital
organs such as lungs, liver, brain and heart for better health. The aim
of this study was to evaluate the effect of the Consciousness Energy
Healing Treated test formulation on the function of vital organs in
various cell-based assays. The test formulation and the cell media was
divided into two parts; one untreated (UT) and other part received the
Biofield Energy Treatment remotely by a renowned Biofield Energy Healer,
Thomas Charles Slade, USA and were labeled as the Biofield Energy
Treated (BT) test formulation/media. Cell viability data suggested that
the tested formulation was safe and non-toxic in nature in six different
cells. The experimental groups like the untreated medium (UT-Med) +
Biofield Treated Test Item (BT-TI) and BT-Med + BT-TI groups showed
74.4\% (at 10 \selectlanguage{greek}µ\selectlanguage{english}g/mL) and 73.7\% (at 1 \selectlanguage{greek}µ\selectlanguage{english}g/mL) restoration of cell
viability, respectively in human cardiac fibroblasts cells (HCF)
compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI and
BT-Med + BT-TI groups showed 76.4\% (at 10 \selectlanguage{greek}µ\selectlanguage{english}g/mL) and 87.5\% (at 1
\selectlanguage{greek}µ\selectlanguage{english}g/mL) restoration of cell viability, respectively in human hepatoma
cells (HepG2) compared to the untreated group. Furthermore, 209.5\%,
757.8\% and 836.2\% restoration of cell viability was observed in
adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med +
BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively, at 1
\selectlanguage{greek}µ\selectlanguage{english}g/mL compared to the untreated. Alkaline phosphatase (ALP) level was
significantly increased by 71.7\%, 71.9\% and 56.7\% in the UT-Med +
BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively in human
bone osteosarcoma cells (MG-63) at 50 \selectlanguage{greek}µ\selectlanguage{english}g/mL compared to the untreated.
Additionally, the level of ALP was also significantly increased by
124.9\% and 106.3\% in the BT-Med + BT-TI group at 25 and 50 \selectlanguage{greek}µ\selectlanguage{english}g/mL,
respectively in human endometrial adenocarcinoma cells (Ishikawa)
compared to the untreated. The percent protection of HCF (heart) cells
(decreased of LDH activity) was significantly increased by 88.3\% and
75.5\% in the BT-Med + BT-TI group at 1 and 10 \selectlanguage{greek}µ\selectlanguage{english}g/mL, respectively;
while 82.8\% (at 0.1 \selectlanguage{greek}µ\selectlanguage{english}g/mL) in the UT-Med + BT-TI group as compared to
the untreated in HCF cells. The percent protection of HepG2 (liver)
cells (decreased of ALT activity) was significantly increased by 47.5\%,
79.8\% and 94\% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI
groups, respectively at 1 \selectlanguage{greek}µ\selectlanguage{english}g/mL compared to the untreated in HepG2
cells. The percent protection of A549 (lungs) cells (increased of SOD
activity) was significantly increased by 67.4\%, 60.8\% and 80.7\% in
the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups,
respectively at 10 \selectlanguage{greek}µ\selectlanguage{english}g/mL; while 137\% (at 0.1 \selectlanguage{greek}µ\selectlanguage{english}g/mL) in the BT-Med +
BT-TI group as compared to the untreated group. Serotonin level was
significantly increased by 225.7\% (at 1 \selectlanguage{greek}µ\selectlanguage{english}g/mL), 176.1\% (at 25 \selectlanguage{greek}µ\selectlanguage{english}g/mL)
and 175.7\% (at 63 \selectlanguage{greek}µ\selectlanguage{english}g/mL) in the BT-Med + BT-TI group; while 317.9\% (at
1 \selectlanguage{greek}µ\selectlanguage{english}g/mL) in the UT-Med + BT-TI group as compared to the untreated in
human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of
vitamin D receptor (VDR) was significantly increased by 195.3\% (at 1
\selectlanguage{greek}µ\selectlanguage{english}g/mL), 176.2\% (at 10 \selectlanguage{greek}µ\selectlanguage{english}g/mL) and 194.7\% (at 50 \selectlanguage{greek}µ\selectlanguage{english}g/mL) in the BT-Med +
BT-TI group compared to the untreated group in MG-63 cells. Altogether
data suggest that these results suggest that Biofield Energy Treated
test formulation significantly protect the major organs viz. bones,
heart, liver, lungs and brain and also improved their functions.
Therefore, The Biofield Energy Treatment (The Trivedi Effect\selectlanguage{ngerman}®) can be
used as a complementary and alternative therapy against several
disorders such as heart attack, heart failure, coronary artery disease,
arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver
cancer, hemochromatosis, Wilson disease, asthma, pneumonia, chronic
bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.%
\end{abstract}\selectlanguage{ngerman}%



\sloppy


\textbf{Journal Name:}~Journal of Biochemistry \& Molecular Medicine

\textbf{Date of Publication:}~21-07-2019

\textbf{ISSN:}~2641-6948

\textbf{Volume:}~1

\textbf{Issue:}~2

\textbf{Page No:}~41-53

\textbf{\textbf{Journal Web
URL:}}~\url{http://www.scitcentral.com/article.php?journal=29\&article=861}

\textbf{~\textbf{Journal PDF
URL:}}~\url{https://www.scitcentral.com/documents/9892dbcb8ffa103eb193b191d13ca854.pdf}

\textbf{Publisher:}~Scitcentral

\textbf{Keywords:}~Cardiac health, Liver health, Brain health, Bone
health, Lungs health, The Trivedi Effect\selectlanguage{ngerman}®, Consciousness energy healing,
VDR receptor

\textbf{Citation:}~Slade TC, Trivedi MK, Branton A, Trivedi D, Nayak G,
et al. (2019) Protective Role of the Biofield Energy Treated Test
Formulation on Vital Organs Function using Cell-Based Assays. J Biochem
Mol Med, 1(2): 41-53.

\selectlanguage{english}
\FloatBarrier
\end{document}

